----

----

**FORM      10-QSB**

**INHIBITON      THERAPEUTICS, INC.**

| **NEVADA**                                     | **88-0448626**                     |
|------------------------------------------------|------------------------------------|
| (State                or other jurisdiction of | (IRS                Employer       |
| incorporation                or organization)  | Identification                No.) |

**7315      East Peakview Avenue**

**Englewood,      Colorado 80111**

**(303)      796-8940**

**Organic      Soils.Com, Inc.**

**300      East 54**
**th**

**      Avenue, Suite 202, Anchorage, AK 99518**

**December      31**

----

**INHIBITON      THERAPEUTICS, INC.**

**(FORMERLY      ORGANIC SOILS.COM, INC.)**

**(A      Development Stage Company)**

**Index      to Financial Statements**

**(Unaudited)**

|                                                                                                                                                                                                                                                                                                                                                                                                                                         | **Page** |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Condensed                  Balance Sheet at October 31, 2005                                                                                                                                                                                                                                                                                                                                                                                 | F-1      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                         |     |
| Condensed                  Statements of Operations for the three and nine months ended October                  31,                  2005, three months ended October 31, 2004, for the period from                  May 11,                  2004 (Inception) through October 31, 2004, and for the period from                  from                  May 11, 2004 (Inception) through October 31, 2005                                   | F-2      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                         |     |
| Condensed                  Statement of Changes in Shareholders' Deficit for the period from                  May 11,                  2004 (Inception) through October 31, 2005                                                                                                                                                                                                                                                             | F-3      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                         |     |
| Condensed                  Statements of Cash Flows for the nine months ended October 31,                  2005, for                  the period from May 11, 2004 (Inception) through October 31, 2004                  for the                  period from May 11, 2004 (Inception) through October 31, 2004 and                  for the                  period from May 11, 2004 (Inception) through October 31,                  2005 | F-4      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                         |     |
| Notes                  to condensed financial statements                                                                                                                                                                                                                                                                                                                                                                                     | F-5      |

----

**INHIBITON      THERAPEUTICS, INC.**

**(FORMERLY      ORGANIC SOILS.COM, INC.)**

**(A      Development Stage Company)**

**Condensed      Balance Sheet**

**(Unaudited)**

**October      31, 2005**

| **Assets**                                                      |   |
|-----------------------------------------------------------------|--------|
| Cash                                                            |   | $ | 691 |   |
| Prepaid                expense                                  |   |   | 16,667 |   |
|                                                            |   |   |   |   |
| Total                assets                                     |   | $ | 17,358 |   |
|                                                            |   |   |   |   |
| **Liabilities                and Shareholders’ Deficit**  |
| Current                liabilities:                             |   |   |   |   |
| Accounts                and notes payable                       |   | $ | 66,079 |   |
| Accounts                and notes payable,                      |   |   |   |   |
| related                party (Note 2)                           |   |   | 418,899 |   |
| Convertible                notes payable                        |   |   | 225,000 |   |
| Accrued                interest payable:                        |   |   |   |   |
| Related                party (Note 2)                           |   |   | 9,614 |   |
| Convertible                notes                                |   |   | 19,978 |   |
|                                                            |   |   |   |   |
| Total                current liabilities                        |   |   | 739,570 |   |
|                                                            |   |   |   |   |
| Commitments                and contingencies                    |   |   | — |   |
|                                                            |   |   |   |   |
| Shareholders’                deficit (Note 5):            |   |   |   |   |
| Common                stock                                     |   |   | 13,451 |   |
| Additional                paid-in capital                       |   |   | 370,130 |   |
| Deficit                accumulated during the development stage |   |   | (1,105,793 | ) |
|                                                            |   |   |   |   |
| Total                shareholders' deficit                      |   |   | (722,212 | ) |
|                                                            |   |   |   |   |
| Total                liabilities and shareholders' deficit      |   | $ | 17,358 |   |

----

**INHIBITON      THERAPEUTICS, INC.**

**(FORMERLY      ORGANIC SOILS.COM, INC.)**

**(A      Development Stage Company)**

**Condensed      Statements of Operations**

**(Unaudited)**

|                                                            |   | **Three                    months ended October 31,** |       | **Three                    months ended October 31,** |   | **Nine                    months ended October 31,** |   | **For                    the period from May 11, 2004 (Inception) through October 31,** |       | **For                    the period from May 11, 2004 (Inception) through October 31,** |   |
|-----------------------------------------------------------------|--------|-------------------------------------------------------|------------|-------------------------------------------------------|--------|------------------------------------------------------|--------|-----------------------------------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------|--------|
|                                                            |   | **2005**                                              |       | **2004**                                              |   | **2005**                                             |   | **2004**                                                                                |       | **2005**                                                                                |   |
| Operating                    costs and expenses:                |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Research                    and development                     |   | $                                                     | 75,000     |                                                  | $      | 75,000                                               |   | $                                                                                       | 225,000    |                                                                                    | $      | 75,000 |   | $ | 375,000 |   |
| Selling,                    general and administrative expenses |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Related                    party (Note 2)                       |   |                                                  | 32,250     |                                                  |   | 60,000                                               |   |                                                                                    | 87,550     |                                                                                    |   | 60,000 |   |   | 456,425 |   |
| Other                                                           |   |                                                  | 37,152     |                                                  |   | 22,190                                               |   |                                                                                    | 227,315    |                                                                                    |   | 22,190 |   |   | 236,621 |   |
| Stock                    based compensation                     |   |                                                  | —    |                                                  |   | —                                              |   |                                                                                    | —    |                                                                                    |   | — |   |   | 1,000 |   |
|                                                            |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Total                    operating costs and expenses           |   |                                                  | (144,402   | )                                                     |   | (157,190                                             | )      |                                                                                    | (539,865   | )                                                                                       |   | (157,190 | ) |   | (1,069,046 | ) |
|                                                            |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Interest                    expense                             |   |                                                  | (10,976    | )                                                     |   | (767                                                 | )      |                                                                                    | (31,309    | )                                                                                       |   | (767 | ) |   | (36,747 | ) |
|                                                            |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Loss                    before income taxes                     |   |                                                  | (155,378   | )                                                     |   | (157,957                                             | )      |                                                                                    | (571,174   | )                                                                                       |   | (157,957 | ) |   | (1,105,793 | ) |
|                                                            |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Income                    tax provision (Note 3)                |   |                                                  | —    |                                                  |   | —                                              |   |                                                                                    | —    |                                                                                    |   | — |   |   | — |   |
|                                                            |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Net                    loss                                     |   | $                                                     | (155,378   | )                                                     | $      | (157,957                                             | )      | $                                                                                       | (571,174   | )                                                                                       | $      | (157,957 | ) | $ | (1,105,793 | ) |
|                                                            |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Basic                    and diluted loss per share             |   | $                                                     | (0.01      | )                                                     | $      | (78.98                                               | )      | $                                                                                       | (0.04      | )                                                                                       |   |   |   |   |   |   |
|                                                            |   |                                                  |       |                                                  |   |                                                 |   |                                                                                    |       |                                                                                    |   |   |   |   |   |   |
| Weighted                    average common shares outstanding   |   |                                                  | 12,126,467 |                                                  |   | 2,000                                                |   |                                                                                    | 13,451,000 |                                                                                    |   |   |   |   |   |   |

----

**INHIBITON      THERAPEUTICS, INC.**

**(FORMERLY      ORGANIC SOILS.COM, INC.)**

**(A      Development Stage Company)**

**Condensed      Statement of Changes in Shareholders’ Deficit**

**(Unaudited)**

|                                                          |   |   |                              |   |                           |   |                            |    | **Deficit**                            |   |      |   |
|---------------------------------------------------------------|--------|--------|-----------------------------------|--------|--------------------------------|--------|---------------------------------|---------|----------------------------------------|--------|-----------|--------|
|                                                          |   |   |                              |   |                           |   | **Additional**                  |    | **accumulated**                        |   |      |   |
|                                                          |   |   | **Common                  Stock** |   | **paid-in**                    |   | **during                  the** |    |                                   |   |
|                                                          |   |   | **Shares**                        |   | **Par                  value** |   | **capital**                     |    | **development                  stage** |   | **Total** |   |
| Balance                  at May 11, 2004                      |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| Inception                  date                               |   |   |                              |   | —                        |   | $                               | — |                                   | $      | —   |   | $ | — |   | $ | — |   |
|                                                          |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| October                  2004 and January 2005,               |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| sale                  of common stock                         |   | *      |                              |   | 9,555,100                      |   |                            | 9,555   |                                   |   | 269,945   |   |   | — |   |   | 279,500 |   |
| October                  2004, issuance of common stock       |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| for                  debt issue costs                         |   | *      |                              |   | 963,000                        |   |                            | 963     |                                   |   | (63       | )      |   | — |   |   | 900 |   |
| December                  2004, issuance of common stock      |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| for                  services                                 |   | *      |                              |   | 107,000                        |   |                            | 107     |                                   |   | 893       |   |   | — |   |   | 1,000 |   |
| January                  2005, conversion of notes payable to |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| common                  stock                                 |   | *      |                              |   | 74,900                         |   |                            | 75      |                                   |   | 625       |   |   | — |   |   | 700 |   |
| Net                  loss                                     |   |   |                              |   | —                        |   |                            | — |                                   |   | —   |   |   | (534,619 | ) |   | (534,619 | ) |
|                                                          |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| Balance                  at February 1, 2005                  |   | *      |                              |   | 10,700,000                     |   |                            | 10,700  |                                   |   | 271,400   |   |   | (534,619 | ) |   | (252,519 | ) |
|                                                          |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| February                  and March 2005,                     |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| sale                  of common stock (Note 5)                |   | *      |                              |   | 428,000                        |   |                            | 428     |                                   |   | 99,572    |   |   | — |   |   | 100,000 |   |
| Reverse                  acquisition of                       |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| Organic                  Soils.com, Inc. (Note 1)             |   |   |                              |   | 2,323,000                      |   |                            | 2,323   |                                   |   | (842      | )      |   | — |   |   | 1,481 |   |
|                                                          |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| Net                  loss                                     |   |   |                              |   | —                        |   |                            | — |                                   |   | —   |   |   | (571,174 | ) |   | (571,174 | ) |
|                                                          |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| Balance                  at October 31, 2005                  |   |   |                              |   | 13,451,000                     |   | $                               | 13,451  |                                   | $      | 370,130   |   | $ | (1,105,793 | ) | $ | (722,212 | ) |
|                                                          |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |
| *                  Restated. See Note 1.                      |   |   |                              |   |                           |   |                            |    |                                   |   |      |   |   |   |   |   |   |   |

----

**INHIBITON      THERAPEUTICS, INC.**

**(FORMERLY      ORGANIC SOILS.COM, INC.)**

**(A      Development Stage Company)**

**Condensed      Statements of Cash Flows**

**(Unaudited)**

|                                                               |   |  **Nine                months ended October 31,** |     | **For                the period from May 11, 2004 (Inception) through Otober 31,** |   | **For                the period from May 11, 2004 (Inception) through October 31,** |   |
|--------------------------------------------------------------------|--------|--------------------------------------------------------|----------|------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------------|--------|
|                                                               |   |  **2005**                                         |     | **2004**                                                                           |   | **2005**                                                                            |   |
| Net                cash used in                                    |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| operating                activities                                |   | $                                                      | (631,504 | )                                                                                  | $      | (177,120                                                                            | )      | $ | (955,777 | ) |
|                                                               |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Cash                flows from financing activities:               |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Proceeds                from related party, notes payable (Note 2) |   |                                                   | 328,000  |                                                                               |   | —                                                                             |   |   | 361,500 |   |
| Proceeds                from notes payable, other                  |   |                                                   | 30,000   |                                                                               |   | —                                                                             |   |   | 30,000 |   |
| Proceeds                from convertible promissory note           |   |                                                   | —  |                                                                               |   | 225,000                                                                             |   |   | 225,000 |   |
| Payments                on related party, notes payable            |   |                                                   | (39,532  | )                                                                                  |   | —                                                                             |   |   | (39,532 | ) |
| Proceeds                from issuance of common stock              |   |                                                   | 100,000  |                                                                               |   | 200                                                                                 |   |   | 379,500 |   |
| Net                cash provided by                                |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| financing                activities                                |   |                                                   | 418,468  |                                                                               |   | 225,200                                                                             |   |   | 956,468 |   |
|                                                               |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Net                change in cash and                              |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| cash                equivalents                                    |   |                                                   | (213,036 | )                                                                                  |   | 48,080                                                                              |   |   | 691 |   |
|                                                               |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Cash                and cash equivalents:                          |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Beginning                of period                                 |   |                                                   | 213,727  |                                                                               |   | —                                                                             |   |   | — |   |
|                                                               |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| End                of period                                       |   | $                                                      | 691      |                                                                               | $      | 48,080                                                                              |   | $ | 691 |   |
|                                                               |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Supplemental                disclosure of cash flow information:   |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Cash                paid during the year for:                      |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Income                taxes                                        |   | $                                                      | —  |                                                                               | $      | —                                                                             |   | $ | — |   |
| Interest                                                           |   | $                                                      | —  |                                                                               | $      | —                                                                             |   | $ | — |   |
|                                                               |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Noncash                financing transactions:                     |   |                                                   |     |                                                                               |   |                                                                                |   |   |   |   |
| Notes                payable converted to stock                    |   | $                                                      | —  |                                                                               | $      | —                                                                             |   | $ | 700 |   |
| Stock                issued in exchange for debt issue costs       |   | $                                                      | —  |                                                                               | $      | —                                                                             |   | $ | 900 |   |

----

**INHIBITON              THERAPEUTICS, INC.**

**(FORMERLY              ORGANIC SOILS.COM, INC.)**

**(A              Development Stage Company)**

**Notes              to Condensed Financial Statements**

**(Unaudited)**

**Note      1: **
**Basis      of presentation**

**Reorganization**

**Note      2: **
**Related      Party**

----

**INHIBITON              THERAPEUTICS, INC.**

**(FORMERLY              ORGANIC SOILS.COM, INC.)**

**(A              Development Stage Company)**

**Notes              to Condensed Financial Statements**

**(Unaudited)**

**Note      3: **
**Income      Tax**

**Note      4: **
**Promissory      Note**

----

**INHIBITON          THERAPEUTICS, INC.**

**(FORMERLY          ORGANIC SOILS.COM, INC.)**

**(A          Development Stage Company)**

**Notes          to Condensed Financial Statements**

**(Unaudited)**

**Note      5: **
**Capital      Stock**

----

----

**Off-Balance      Sheet Arrangements.**

**PART      II - OTHER INFORMATION**

----

| **Exhibits:** |                                                                                                      |
|---------------|-----------------------------------------------------------------------------------------------------------|
| 31.1          | CEO                Certification pursuant to Section 302 of the Sarbanes-Oxley Act of                2002 |
| 32.1          | CEO                Certification pursuant to Section 906 of the Sarbanes-Oxley Act of                2002 |

----

|   | **INHIBITON                THERAPEUTICS, INC.** |
|--------|-------------------------------------------------|
|   | (Registrant)                                    |

| Date:                December                15, 2005 | By:                /s/                Henry Fong      |
|-------------------------------------------------------|-------------------------------------------------------|
|                                                  | Henry                Fong                             |
|                                                  | President,                Chief Executive Officer and |
|                                                  | Chief                Financial Officer                |

----

----